Evidence map›Paper›PMID 35680278›Full record

ArticleBMJ case reports2022

Late-onset Fabry disease: the cardiac sequela.

John Tremblay, Samuel Kim, Edward Philbin, Kelly Beers, Andrea Lightle, Dmitri Belov

Open access · greenAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

John TremblayInternal Medicine, Albany Medical Center, Albany, New York, USA tremblj2@amc.edu.
Samuel KimDepartment of Cardiology, Albany Medical Center, Albany, New York, USA.
Edward PhilbinDepartment of Cardiology, Albany Medical Center, Albany, New York, USA.
Kelly BeersDepartment of Nephrology, Albany Medical Center, Albany, New York, USA.
Andrea LightleDepartment of Pathology, Albany Medical Center, Albany, New York, USA.
Dmitri BelovDepartment of Cardiology, Albany Medical Center, Albany, New York, USA.
Albany Medical Center Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe a patient with Fabry disease (FD) who initially presented with atrial fibrillation without left ventricular hypertrophy (LVH) 14 years before being correctly diagnosed with FD. In the interim, he survived a myocardial infarction complicated by ventricular fibrillation, and his severe LVH was misdiagnosed as sarcomeric hypertrophic cardiomyopathy. In the following 4 years, he developed proteinuric kidney disease, neuropathy, sensorineural hearing loss and gastrointestinal symptoms. The patient was eventually readmitted for an overt heart failure (HF) exacerbation and was seen by an HF cardiologist. The constellation of systemic findings led to further diagnostic testing, including an endomyocardial biopsy, tests to determine alpha-galactosidase A enzyme activity and α-galactosidase A gene (GLA) analysis. The results of the patient's tests were consistent with FD and he was started on enzyme replacement therapy. To our knowledge, this is the first detailed description of a late-onset phenotype of FD with c.146 G>C GLA variant. In addition, this case serves as a potent reminder to pay meticulous attention to 'red flags' accompanying LVH.

Indexed as

Cardiomyopathy, HypertrophicFabry Diseasealpha-GalactosidaseEnzyme Replacement TherapyHumansHypertrophy, Left VentricularLate Onset DisordersMalealpha-GalactosidaseArrhythmiasCardiovascular systemHeart failure

Identifiers

PMID35680278
PMCPMC9185384
OpenAlexW4281776161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.